BridgeBio Pharma Inc. has published a document detailing findings from a sponsored genetic testing program on non-surgical hypoparathyroidism. The document highlights that gain-of-function CASR variants are a significant genetic contributor to this condition. It also provides statistics on the frequency of detected variants across different genes and outlines eligibility criteria for potential participation in clinical trials. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on July 12, 2025, and is solely responsible for the information contained therein.